{ "items": [ "\n\n
\n \n 11 February 2021\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 2 February 2021\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 15 January 2021\n \n
\n\n \n \n \n\n \n \n \nStatement from the RECOVERY trial chief investigators, 15 January 2021
\n \n\n\n \n 11 January 2021\n \n
\n\n \n \n \n\n \n \n \nStatement from the RECOVERY trial chief investigators, 11 January 2021
\n \n\n\n \n 18 December 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 14 December 2020\n \n
\n\n \n \n \n\n \n \n \nStatement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on azithromycin, 14 December 2020
\n \n\n\n \n 30 November 2020\n \n
\n\n \n \n \n\n \n \n \nThe RECOVERY trial has been selected as one of ten finalists in the Special COVID-19 response category in the 2020 National Project Awards, organised by PMI UK, in association with PricewaterhouseCoopers (PwC).
\n \n\n\n \n 27 November 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 13 November 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 9 November 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 6 November 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 5 November 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 30 October 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 26 October 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 5 October 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 14 September 2020\n \n
\n\n \n \n \n\n \n \n \nOne of the world\u2019s largest efforts to find effective COVID-19 treatments will evaluate the impact of REGN-COV2 on mortality, hospital stays, and the need for ventilation.
\n \n\n\n \n 29 June 2020\n \n
\n\n \n \n \n\n \n \n \nStatement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir, 29 June 2020
\n \n\n\n \n 16 June 2020\n \n
\n\n \n \n \n\n \n \n \nStatement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on dexamethasone, 16 June 2020
\n \n\n\n \n 5 June 2020\n \n
\n\n \n \n \n\n \n \n \nStatement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020
\n \n\n\n \n 3 June 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n